NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD
54.87
+0.49 (+0.9%)
The current stock price of EXAS is 54.87 USD. In the past month the price increased by 3.41%. In the past year, price increased by 27.81%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.48 | 335.32B | ||
AMGN | AMGEN INC | 13.99 | 156.11B | ||
GILD | GILEAD SCIENCES INC | 14.53 | 139.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.23B | ||
ARGX | ARGENX SE - ADR | 101.9 | 35.78B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.54 | 27.66B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
NTRA | NATERA INC | N/A | 22.36B | ||
BIIB | BIOGEN INC | 8.42 | 19.51B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.29B |
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
EXACT SCIENCES CORP
5505 Endeavor Lane
Madison WISCONSIN 53719 US
CEO: Kevin T. Conroy
Employees: 6900
Phone: 16082845700
The current stock price of EXAS is 54.87 USD. The price increased by 0.9% in the last trading session.
The exchange symbol of EXACT SCIENCES CORP is EXAS and it is listed on the Nasdaq exchange.
EXAS stock is listed on the Nasdaq exchange.
34 analysts have analysed EXAS and the average price target is 70.68 USD. This implies a price increase of 28.81% is expected in the next year compared to the current price of 54.87. Check the EXACT SCIENCES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EXACT SCIENCES CORP (EXAS) has a market capitalization of 10.35B USD. This makes EXAS a Large Cap stock.
EXACT SCIENCES CORP (EXAS) currently has 6900 employees.
EXACT SCIENCES CORP (EXAS) has a support level at 54.86 and a resistance level at 55.76. Check the full technical report for a detailed analysis of EXAS support and resistance levels.
The Revenue of EXACT SCIENCES CORP (EXAS) is expected to grow by 12.81% in the next year. Check the estimates tab for more information on the EXAS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EXAS does not pay a dividend.
EXACT SCIENCES CORP (EXAS) will report earnings on 2025-07-29, after the market close.
EXACT SCIENCES CORP (EXAS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.51).
The outstanding short interest for EXACT SCIENCES CORP (EXAS) is 5.98% of its float. Check the ownership tab for more information on the EXAS short interest.
ChartMill assigns a technical rating of 8 / 10 to EXAS. When comparing the yearly performance of all stocks, EXAS is one of the better performing stocks in the market, outperforming 86.64% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to EXAS. EXAS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months EXAS reported a non-GAAP Earnings per Share(EPS) of -5.51. The EPS decreased by -317.42% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -17.86% | ||
ROE | -42.55% | ||
Debt/Equity | 0.97 |
ChartMill assigns a Buy % Consensus number of 85% to EXAS. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of 89.86% and a revenue growth 12.81% for EXAS